Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
复制标题
DOI：
10.18632/oncotarget.11565
复制
发表时间：
2016-10-11
期刊：
影响因子：
--
通讯作者：
Frassineti GL
中科院分区：
文献类型：
--
作者：
Casadei Gardini A;Scarpi E;Faloppi L;Scartozzi M;Silvestris N;Santini D;de Stefano G;Marisi G;Negri FV;Foschi FG;Valgiusti M;Ercolani G;Frassineti GL
我们评估了全身免疫炎症指数（SII）、中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR），目的是探讨它们在索拉非尼治疗的晚期肝细胞癌（HCC）患者中的预后价值。我们分析了56例接受索拉非尼治疗的晚期HCC患者。治疗开始前和治疗1个月后分别测定淋巴细胞、中性粒细胞和血小板。SII≥360的患者与SII < 360的患者相比，中位PFS （2.6 vs 3.9个月，P < 0.026）和OS （5.6 vs 13.9个月，P = 0.027）较低。与NLR < 3的患者相比，NLR≥3的中位PFS （2.6 vs 3.3个月，P < 0.049）较低，但OS （5.6 vs 13.9个月，P = 0.062）较低。在调整临床协变量后，SII和NLR仍然是OS的独立预后因素。SII和NLR是索拉非尼治疗晚期HCC患者的潜在预后指标。
We evalueted a systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored their prognostic value in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. 56 advanced HCC patients receiving sorafenib were available for our analysis. Lymphocyte, neutrophil and platelet were measured before beginning of treatment and after one month. Patient with SII ≥ 360 showed lower median PFS (2.6 vs. 3.9 months, P < 0.026) and OS (5.6 vs. 13.9 months, P = 0.027) with respect to patients with SII < 360. NLR ≥ 3 had a lower median PFS (2.6 vs. 3.3 months, P < 0.049) but not OS (5.6 vs. 13.9 months, P = 0.062) than those with NLR < 3. After adjusting for clinical covariates SII and NLR remained an independent prognostic factor for OS. The SII and NLR represent potential prognostic indicator in patients with advanced HCC treated with sorafenib.